Protocol for EpiCom: A phase 3b/4 study of behavioral outcomes following adjunctive cannabidiol for the management of tuberous sclerosis complex-associated neuropsychiatric disorders (TAND).

Protocol for EpiCom: A phase 3b/4 study of behavioral outcomes following adjunctive cannabidiol for the management of tuberous sclerosis complex-associated neuropsychiatric disorders (TAND).

Show other versions (1)

Tuberous sclerosis complex (TSC)-associated neuropsychiatric disorders (TAND) affect ≈90% of individuals with TSC and significantly reduce their quality of life (QoL). However, there are limited studies assessing pharmacotherapy for TAND. A plant-derived highly purified pharmaceutical formulation of...

Full description

Saved in:
Bibliographic Details
Main Authors: Agnies M van Eeghen, Elizabeth A Thiele, Sam Amin, Debopam Samanta, Anna C Jansen, Joanne Stevens, Lisa Moore-Ramdin, Petrus J de Vries
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2025-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0324648
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items